Creative BioMart is a well-known expert who is committed to developing a variety of protein therapies to improve the effectiveness and safety of protein therapy, and to allow the production of new types of proteins and effects. With years of experience, we provide customized services for enzyme as protein therapeutics to precisely meet customer requirements.

Introduction of Enzyme Replacement Therapy

Enzymes are one of these small but important components of healthy bodily function. They are responsible for interacting with other chemicals in the body to cause certain reactions, such as converting complex sugars into usable energy. Enzyme replacement therapy (ERT) is primarily based on the regular intravenous injection of specific enzymes produced by recombinant DNA technology and is best suited for the many available therapies for lysosomal storage disorders. Replacement of defective enzymes and restoration of enzyme activity with recombinant human enzymes in lysosomal storage diseases (LSDs). Replacement enzymes for ERT are derived from human, animal, and plant cells, which are then genetically modified and processed before being delivered to patients. By accepting these enzyme replacements, the body is able to successfully perform functions that are inhibited by the deficiency.

Fig 1. Schematic representation for the remaining challenges in the enzyme replacement therapy. (Safary A, 2018)

Services

Enzymes have high affinity and specificity for substrates, and can catalyze the conversion of a variety of target molecules into desired products. These two properties make enzymes useful as a special kind of drug to perform therapeutic biochemical reactions that small molecules cannot. As a leading service provider of protein engineering, Creative BioMart has established a powerful enzyme-based protein therapeutics platform, providing more than 100 functional enzyme development services, including L-asparaginase, arginine deiminase, glutathione aminoamidase, β-glucuronidase, phenylalanine aminolyase, iduronate-2-sulfatase, N-acetylgalactosamine- 4-sulfatase, lysosomal acid alpha-glucosidase, arabinoside enzyme, adenosine deaminase, etc.

The large molecular weight, immunogenicity, short half-life and high purity requirements of enzymes are the key factors limiting the use of enzymes. Our scientists are working to develop a variety of technologies to produce and modulate the properties of therapeutic enzymes. Our strategies include but are not limited to:

• Targeted enzyme delivery system: we overcome the restriction of enzyme access to difficult pathological sites by increasing the presence of M6P residues on the recombinase or increasing the expression rate of M6PRs on target cells to increase the cellular uptake of the enzyme.
• Nanobiomaterials: we enhance the efficacy of ERT through the use of advanced nanobiomaterials,such as biodegradable nanomicelles, nanoliposomes and lipid based nanoparticles. In addition, nanobiomaterials can also protect recombinant enzymes from unwanted biological effects, non-selective biodistribution by increasing drug absorption, controlling release of enzyme supply, pharmacokinetic (PK) or pharmacodynamic (PD) properties, and improving the pharmacological response.

Creative BioMart is committed to providing new technologies and means for adjusting the biochemical and biophysical properties of therapeutic enzymes to meet the special needs of applications through the development of protein engineering. We will work with you to develop the most appropriate strategy and provide the most meaningful data for your research for accelerating the research of life sciences. If you are interested in our services, please do not hesitate to contact us for more information.

Reference

1. Safary A, Khiavi M A, Mousavi R, et al.. (2018) Enzyme replacement therapies: what is the best option?. BioImpacts: BI. 8(3): 153.

• Engineering of Therapeutic Antibodies
• Engineering of Therapeutic Coagulation Factors
• Engineering of Therapeutic Cytokines and Receptors
• Engineering of Therapeutic Major Histocompatibility Complex Proteins
• Engineering of Therapeutic Protein Hormones
• Engineering of Therapeutic T Cell Receptors
• Engineering of Therapeutic TCR-Like Antibodies